Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 706-715

  Darpo, Borje ^a   Ferber, Georg ^b   Siegl, Peter ^c   Laurijssens, Bart ^d   Macintyre, Fiona ^e   Toovey, Stephen ^f   Duparc, Stephan ^e  

^a DANDERYD HOSPITAL   (Sweden)

^b Georg Ferber Statistical Consultant   (Switzerland)

^c Siegl Pharma Consulting LLC   (United States)

^d BEL Pharm Consulting   (France)

^e Medicines for Malaria Venture   (Switzerland)

^f Pegasus Research   (United Kingdom)

Author keywords

exposure response; malaria; OZ439; piperaquine; QT; QTc

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ; OZ 439; PIPERAQUINE; PLACEBO; UNCLASSIFIED DRUG; ADAMANTANE; PEROXIDE; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAM; FEMALE; HEART RATE; HEART REPOLARIZATION; HUMAN; HUMAN EXPERIMENT; MALARIA; MALE; MAXIMUM DRUG EFFECT; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; QT PROLONGATION; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; LONG QT SYNDROME; MIDDLE AGED; YOUNG ADULT;

ADAMANTANE; ADOLESCENT; ADULT; ANTIMALARIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEALTHY VOLUNTEERS; HEART RATE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; PEROXIDES; QUINOLINES; YOUNG ADULT;

EID: 84942519707     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12680     Document Type: Article

References (28)

1. World Health Organization. World malaria report. Geneva, Switzerland: WHO, 2013.
2. Argiun PM, Tan KR,. Malaria. In: Travelers Health, ed., Brunette GW, Atlanta, GA, USA: Center for Disease Control and Prevention, 2014.
3. Breslin TM, Ionmhain UN, Bergin C, Gallagher D, Collins N, Kinsella N, McMahon G,. Malarial cases presenting to a European urban Emergency Department. Eur J Emerg Med 2013; 20: 115-9.
4. Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, Chy S, Duong S, Leang R, Ringwald P, Dondorp AM, Tripura R, Benoit-Vical F, Berry A, Gorgette O, Ariey F, Barale JC, Mercereau-Puijalon O, Menard D,. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother 2013; 57: 914-23.
5. Dondorp AM, Ringwald P,. Artemisinin resistance is a clear and present danger. Trends Parasitol 2013; 29: 359-60.
6. Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, Hadi CM, Chansolme DH, Murphy HA, Melek BH, Tenaglia AN, Mushatt DM, Dreisbach AW, Lertora JJ, Krogstad DJ,. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007; 2: e6.
7. White NJ,. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7: 549-58.
8. Eurartesim. EU Summary of Product Characteristics [Online]. 2011. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001199/WC500118113.pdf (last accessed 8 June 2015).
9. Sanchez-Chapula JA, Salinas-Stefanon E, Torres-Jacome J, Benavides-Haro DE, Navarro-Polanco RA,. Blockade of currents by the antimalarial drug chloroquine in feline ventricular myocytes. J Pharmacol Exp Ther 2001; 297: 437-45.
10. Borsini F, Crumb W, Pace S, Ubben D, Wible B, Yan GX, Funck-Brentano C,. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother 2012; 56: 3261-70.
11. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan GX,. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006; 3: 948-56.
12. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG,. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32-45.
13. Zhu H, Wang Y, Gobburu JV, Garnett CE,. Considerations for clinical trial design and data analyses of thorough QT studies using drug-drug interaction. J Clin Pharmacol 2010; 50: 1106-11.
14. Darpo B, Sarapa N, Garnett C, Benson C, Dota C, Ferber G, Jarugula V, Johannesen L, Keirns J, Krudys K, Ortemann-Renon C, Riley S, Rogers-Subramaniam D, Stockbridge N,. The IQ-CSRC prospective clinical Phase 1 study: "Can early QT assessment using exposure response analysis replace the thorough QT study?". Ann Noninvasive Electrocardiol 2014; 19: 70-81.
15. Darpo B, Benson C, Dota C, Ferber G, Garnett CE, Green CL, Jarugula V, Johannesen L, Keirns J, Krudys K, Liu K, Ortemann-Renon C, Riley S, Sarapa N, Smith B, Stolz R, Zhou M, Stockbridge N,. Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase. Clin Pharmacol Ther 2015; 97: 326-35. DOI: 10.1002/cpt.60.
16. Fridericia LS,. Die Systolendauer im Elektrokardiogramm bei normalen Menchen und bei Herzkranken. Acta Med Scand 1920; 53: 469-86.
17. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, White NJ, Nosten F, Lindegardh N,. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother 2012; 56: 1997-2007.
18. Eurartesim. Assessment report EMA/739355/2011. Committee for Medicinal Products for Human Use (CHMP) [Online]. 2011. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/001199/WC500118116.pdf (last accessed 8 June 2015).
19. Keating GM,. Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs 2012; 72: 937-61.
20. Manning J, Vanachayangkul P, Lon C, Spring M, So M, Sea D, Se Y, Somethy S, Phann ST, Chann S, Sriwichai S, Buathong N, Kuntawunginn W, Mitprasat M, Siripokasupkul R, Teja-Isavadharm P, Soh E, Timmermans A, Lanteri C, Kaewkungwal J, Auayporn M, Tang D, Chour CM, Prom S, Haigney M, Cantilena L, Saunders D,. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval. Antimicrob Agents Chemother 2014; 58: 6056-67.
21. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D,. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev 2014; CD010927. DOI: 10.1002/14651858.CD010927.
22. Bednar MM, Harrigan EP, Ruskin JN,. Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002; 89: 1316-9.
23. Da CA, Chalvidan T, Belounas A, Messier M, Viallet M, Mansour H, Lamaison D, Djiane P, Isaaz K,. Predictive factors of ventricular fibrillation triggered by pause-dependent torsades de pointes associated with acquired long QT interval: role of QT dispersion and left ventricular function. J Cardiovasc Electrophysiol 2000; 11: 990-7.
24. Darpo B,. Spectrum of drugs prolonging the QT interval and the incidence of torsades de pointes. Eur Heart J 2001; 3: 70-80.
25. ICH E14 Questions & Answers [Online]. 2014. Available at http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-QAs-R2-Step4.pdf (last accessed 8 June 2015).
26. ICH Harmonized Tripartite Guideline E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs [Online]. 2005. Available at http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E14/E14-Guideline.pdf (last accessed 8 June 2015).
27. Darpo B, Garnett C,. Early QT assessment-how can our confidence in the data be improved? Br J Clin Pharmacol 2012; 76: 642-8.
28. Ferber G, Zhou M, Darpo B,. Detection of QTc Effects in small studies-Implications for replacing the thorough QT study. Ann Noninvasive Electrocardiol 2014; Nov 4. DOI: 10.1111/anec.12227. [Epub ahead of print].